Therapeutic Opportunities in the Intrinsic Subtypes of Muscle-Invasive Bladder Cancer

Hematology/Oncology Clinics of North America

Volumn 29, Issue 2, 2015, Pages 377-394

  McConkey, David J ^a   Choi, Woonyoung ^a   Ochoa, Andrea ^a   Siefker Radtke, Arlene ^a   Czerniak, Bogdan ^a   Dinney, Colin P N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Basal and luminal; Neoadjuvant chemotherapy; Urothelial cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHOTREXATE; MPDL 3280A; MYC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P63; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; VASCULOTROPIN; VINBLASTINE; TUMOR MARKER;

BLADDER CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; EXCISION REPAIR; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LYMPHOCYTIC INFILTRATION; MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; CANCER STAGING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PROGNOSIS; TREATMENT OUTCOME; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84933523844     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.11.003     Document Type: Review

References (74)

1. Shah J.B., McConkey D.J., Dinney C.P. New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. Clin Cancer Res 2011, 17(9):2608-2612.
2. Grossman H.B. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. NEngl J Med 2003, 349(9):859-866.
3. Sonpavde G. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 2010, 11(9):861-870.
4. Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507(7492):315-322.
5. Iyer G. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. JClin Oncol 2013, 31(25):3133-3140.
6. Sjodahl G. Amolecular taxonomy for urothelial carcinoma. Clin Cancer Res 2012, 18(12):3377-3386.
7. Choi W. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014, 25(2):152-165.
8. Damrauer J.S. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA 2014, 111(8):3110-3115.
9. Iyer G. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012, 338(6104):221.
10. Dinney C.P. Novel neoadjuvant paradigms for bladder cancer research: results from the National Cancer Center Institute Forum. Urol Oncol 2014, 32(8):1108-1115.
11. Lee J.K. Astrategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA 2007, 104(32):13086-13091.
12. Powles T. Inhibition of PD-L1 by MPDL3280A and clinical activity in patients with metastatic urothelial bladder cancer (UBC). JClin Oncol 2014, 32(suppl):5s. [abstract: 5011].
13. Perou C.M. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
14. Sorlie T. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98(19):10869-10874.
15. Prat A., Ellis M.J., Perou C.M. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 2012, 9(1):48-57.
16. Prat A. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12(5):R68.
17. Esserman L.J. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 2012, 132(3):1049-1062.
18. Esserman L.J. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. JClin Oncol 2012, 30(26):3242-3249.
19. Visvader J.E. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev 2009, 23(22):2563-2577.
20. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61-70.
21. Lozano G. The oncogenic roles of p53 mutants in mouse models. Curr Opin Genet Dev 2007, 17(1):66-70.
22. Zhang X.H. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009, 16(1):67-78.
23. Cooperberg M.R. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 2014, [Epub ahead of print].
24. Lauss M., Ringner M., Hoglund M. Prediction of stage, grade, and survival in bladder cancer using genome-wide expression data: a validation study. Clin Cancer Res 2010, 16(17):4421-4433.
25. Lotan Y. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. Eur Urol 2013, 64(3):465-471.
26. Lindgren D. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010, 70(9):3463-3472.
27. Ho P.L., Kurtova A., Chan K.S. Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nat Rev Urol 2012, 9(10):583-594.
28. Chan K.S. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009, 106(33):14016-14021.
29. Volkmer J.P. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci USA 2012, 109(6):2078-2083.
30. Choi W. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol 2014, 11:400-410.
31. McConkey D.J., Choi W., Dinney C.P. New Insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol 2014, 66:609-610.
32. Taube J.H. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 2010, 107(35):15449-15454.
33. Rebouissou S. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med 2014, 6(244):244ra91.
34. Blaveri E. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005, 11(11):4044-4055.
35. Van Batavia J. Bladder cancers arise from distinct urothelial sub-populations. Nat Cell Biol 2014, 16(10):982-991.
36. Carroll D.K. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol 2006, 8(6):551-561.
37. Hoadley K.A. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014, 158(4):929-944.
38. Cheung K.J., Gabrielson E., Werb Z., et al. Collective invasion in breast cancer requires a conserved basal epithelial program. Cell 2013, 155(7):1639-1651.
39. Ho P.L., Lay E.J., Jian W., et al. Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res 2012, 72(13):3135-3142.
40. Choi W. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One 2012, 7(1):e30206.
41. Karni-Schmidt O. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol 2011, 178(3):1350-1360.
42. Marquis L. p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells. Cancer Biol Ther 2012, 13(7):477-486.
43. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 9(4):265-273.
44. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. JClin Invest 2009, 119(6):1420-1428.
45. Mani S.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133(4):704-715.
46. Tran M.N. The p63 isoform DNp63a inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of miR-205. JBiol Chem 2013, 288:3275-3288.
47. Gregory P.A. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10(5):593-601.
48. Prowell T.M., Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. NEngl J Med 2012, 366(26):2438-2441.
49. Denkert C. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. JClin Oncol 2010, 28(1):105-113.
50. Jackson J.G. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012, 21(6):793-806.
51. Byrski T. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2014, 147(2):401-405.
52. Narod S.A. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 2010, 7(12):702-707.
53. Van Allen E.M. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014, 4(10):1140-1153.
54. Knowles M.A., Platt F.M., Ross R.L., et al. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 2009, 28(3-4):305-316.
55. Knowles M.A. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Future Oncol 2008, 4(1):71-83.
56. Williams S.V., Hurst C.D., Knowles M.A. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013, 22(4):795-803.
57. Lamont F.R. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth invitro and invivo. Br J Cancer 2011, 104(1):75-82.
58. Ching C.B. HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. Mod Pathol 2011, 24(8):1111-1119.
59. Ross J.S. Ahigh frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin Cancer Res 2014, 20(1):68-75.
60. Wang X. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res 2007, 13(3):953-957.
61. Black P.C. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008, 14(5):1478-1486.
62. Haddad Y., Choi W., McConkey D.J. Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res 2009, 15(2):532-542.
63. Witta S.E. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006, 66(2):944-950.
64. Dominick M.A. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol 2006, 34(7):903-920.
65. Egerod F.L., Brunner N., Svendsen J.E., et al. PPARalpha and PPARgamma are co-expressed, functional and show positive interactions in the rat urinary bladder urothelium. JAppl Toxicol 2010, 30(2):151-162.
66. Egerod F.L. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium invivo. Biomarkers 2005, 10(4):295-309.
67. George S.K. Chemoprevention of BBN-induced bladder carcinogenesis by the selective estrogen receptor modulator tamoxifen. Transl Oncol 2013, 6(3):244-255.
68. Hoffman K.L., Lerner S.P., Smith C.L. Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation. Horm Cancer 2013, 4(1):24-35.
69. Shen S.S. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006, 106(12):2610-2616.
70. Hsu I. Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway invitro and invivo. Oncotarget 2014, 5(17):7917-7935.
71. Hsu I. Suppression of ERbeta signaling via ERbeta knockout or antagonist protects against bladder cancer development. Carcinogenesis 2014, 35(3):651-661.
72. Inoue K. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000, 6(12):4866-4873.
73. Slaton J.W. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. JUrol 2004, 171(2 Pt 1):570-574.
74. McConkey D., Choi W., Dinney C. Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sjodahl, and Mattias Hoglund's letter to the editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol 2014;66:609-10. Eur Urol 2014, [Epub ahead of print].